Experienced Life Sciences Professional | Former Biotech C-suite Executive & Healthcare Investment Banker
"WHAT IF" the big surprise of 2024 in biotech is increased interest in #CNS, #neuroscience and #mentalhealth by Big Pharmas (including those that exited the space)? #oncology will continue to dominate biopharma deal activity (rightly so) but there are growing and tangible signs that interest is growing strongly for CNS and mental health indications. 📈 IPOs / follow-on offerings / VC activity: - CNS is the second most popular TA, making consistently makes 10-20% of IPOs (vs. c.35% for oncology). In 2023, big events included Neumora's IPO (partly owned by Amgen), as well as Karuna Therapeutics and Compass Pathways large follow-on offerings - Lykos Therapeutics (formerly MAPS PBC) $100M series A raise, which mark a turning point in the psychedelics-based CNS space 🤝 M&A / licensing / collaborations: - Big transactions included Bristol Myers Squibb's acquisition of Karuna Therapeutics ($14bn) and AbbVie's acquisition of Cerevel Therapeutics ($9bn) - Big licensing / collaboration deals included Roche's agreement with Monte Rosa Therapeutics and Eli Lilly and Company collaboration with Scribe Therapeutics 🚀 Regulatory / commercial updates: - Biogen / Eisai US's full FDA approval of Leqembi to treat Alzheimer, after much drama - Sage Therapeutics / Biogen's FDA approval of Zurzuvae, the first oral drug to treat postpartum depression - Johnson & Johnson's psychedelic drug #Spravato sales booming, with $600M LTM sales and now guidance of $1bn-$5bn peak sales (far from initially expected) A lot is happening and lots of catalysts are expected in 2024. The future is bright. #biotech #drugdiscovery #businessdevelopment #mergersandacquisitions
Changing BioBusiness 1% at a time
9moDon't forget rare diseases, more than ever, biologic pathways and patient insights are driving drug development.